Results of clinical endpoints of a randomized phase It trial with doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer

被引：1
|
作者：
Schneeweiss, A. [1 ]
Ruiz, A. [2 ]
Rovira, P. [3 ]
Bottini, A. [4 ]
Manikhas, A. [5 ]
Wacker, J. [6 ]
Schumacher, T. [7 ]
Wolf, M. [8 ]
Segui, M. [9 ]
Sinn, P. [1 ]
Kennedy, L. [10 ]
Mansouri, K. [11 ]
Bauknecht, T. [11 ]
机构：
[1] Univ Heidelberg, Frauenklin, D-6900 Heidelberg, Germany
[2] Inst Valenciano Oncol, Serv Oncol, Valencia, Spain
[3] Hosp Univ, Serv Oncol, Jaen, Spain
[4] Azienda Inst Ospitalieri, UO Breast Unit, Cremona, Italy
[5] City Oncol Dispensary, Breast Canc Dept, St Petersburg, Russia
[6] Furst Stirum Klin, Frauenklin, Bruchsal, Germany
[7] Kreiskrankenhaus, Sinsheim, Germany
[8] Vivantes Klinikum Urban, Berlin, Germany
[9] Corp Sanit Parc Tauti, Serv Oncol, Sabadell, Spain
[10] Lilly UK, Windlesham, Surrey, England
[11] Lilly Germany, Bad Homburg, Germany
来源：
BREAST | 2009年 / 18卷
关键词：
D O I：
10.1016/S0960-9776(09)70201-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [1] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
  • [2] Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer:: A randomized phase II trial
    Schneeweiss, Andreas
    Lauschner, Ilka
    Ruiz, Amparo
    Guerrero, Angel
    Sanchez-Rovira, Pedro
    Segui, Miguel Angel
    Goerke, Kay
    Wolf, Michael
    Manikhas, Alexey G.
    Wacker, Juergen
    Marme, Frederik
    Lichter, Peter
    Sinn, Hans-Peter
    Sohn, Christof
    Mansouri, Kambiz
    Bauknecht, Thomas
    Hahn, Meinhard
    [J]. CLINICAL BREAST CANCER, 2007, 7 (07) : 555 - 558
  • [3] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data
    Schneeweiss, Andreas
    Ruiz, Amparo
    Manikhas, Alexey
    Bottini, Alberto
    Rovira, Pedro Sanchez
    Mansouri, Kambiz
    Kazeem, Gbenga
    Bauknecht, Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Doxorubicin (A) followed by docetaxel (T) versus doxorubicin plus docetaxel (AT) in the adjuvant treatment of breast cancer (BC)
    Di Leo, A
    Crown, J
    Nogaret, LM
    Duffy, K
    Bartholomeus, S
    Dolci, S
    Rowan, S
    O'Higgins, N
    Riva, A
    Piccart, MJ
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S41 - S41
  • [5] Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer
    Livi, L.
    Meattini, I.
    Cardillo, C. De Luca
    Scotti, V.
    Agresti, B.
    Franzese, C.
    Sanchez, L.
    Nori, J.
    Bertocci, S.
    Cassani, S.
    Bianchi, S.
    Cataliotti, L.
    Biti, G.
    [J]. JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 36 - 39
  • [6] A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
    Yoo, Changhoon
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Kim, Jeong Eun
    Jung, Kyung Hae
    Gong, Gyung-Yub
    Son, Byung-Ho
    Ahn, Sei-Hyun
    Ahn, Seung Do
    Kim, Hak-Hee
    Shin, Hee Jung
    Kim, Woo Kun
    [J]. CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 406 - 415
  • [7] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
    Jones, Stephen E.
    Savin, Michael A.
    Holmes, Frankie Ann
    O'Shaughnessy, Joyce A.
    Blum, Joanne L.
    Vukelja, Svetislava
    McIntyre, Kristi J.
    Pippen, John E.
    Bordelon, James H.
    Kirby, Robert
    Sandbach, John
    Hyman, William J.
    Khandelwal, Pankaj
    Negron, Angel G.
    Richards, Donald A.
    Anthony, Stephen P.
    Mennel, Robert G.
    Boehm, Kristi A.
    Meyer, Walter G.
    Asmar, Lina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5381 - 5387
  • [8] Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: Results of a feasibility study
    Cardoso, F
    Ferreira, AF
    Crown, J
    Dolci, S
    Paesmans, M
    Riva, A
    Di Leo, A
    Piccart, MJ
    [J]. ANTICANCER RESEARCH, 2001, 21 (1B) : 789 - 795
  • [9] Docetaxel followed by epirubicin plus docetaxel as primary systemic therapy for large operable breast cancer
    Frutuoso, Cristina
    Henriques, Isabel
    Pazos, Isabel
    Abraul, Elsa
    Pego, Antonio
    Belo, Joana
    Campos, Ondina
    Gervasio, Helena
    De Oliveira, Carlos F.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 66 - 66
  • [10] Phase-III trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide for primary breast cancer
    Mross, Klaus
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (04) : 253 - 254
12345